These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 30962585)

  • 1. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.
    Hammerich L; Marron TU; Upadhyay R; Svensson-Arvelund J; Dhainaut M; Hussein S; Zhan Y; Ostrowski D; Yellin M; Marsh H; Salazar AM; Rahman AH; Brown BD; Merad M; Brody JD
    Nat Med; 2019 May; 25(5):814-824. PubMed ID: 30962585
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.
    Sultan H; Wu J; Kumai T; Salazar AM; Celis E
    Cancer Immunol Immunother; 2018 Jul; 67(7):1091-1103. PubMed ID: 29696308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
    Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
    J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
    Song W; Levy R
    Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flt3 ligand augments immune responses to soluble PD1-based DNA vaccine via expansion of type 1 conventional DCs.
    Cai Z; Qiao Y; Wuri Q; Zhang K; Qu X; Zhang S; Wu H; Wu J; Wang C; Yu X; Kong W; Zhang H
    Int Immunopharmacol; 2024 Nov; 141():112956. PubMed ID: 39168022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
    Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
    J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice.
    Salem ML; Diaz-Montero CM; El-Naggar SA; Chen Y; Moussa O; Cole DJ
    Vaccine; 2009 Jan; 27(4):549-57. PubMed ID: 19027047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy.
    Matsumoto M; Takeda Y; Seya T
    Expert Opin Biol Ther; 2020 Aug; 20(8):937-946. PubMed ID: 32223572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain tumor immunotherapy with type-1 polarizing strategies.
    Okada H
    Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.
    Pulko V; Liu X; Krco CJ; Harris KJ; Frigola X; Kwon ED; Dong H
    J Immunol; 2009 Sep; 183(6):3634-41. PubMed ID: 19710456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.
    Manzur S; Cohen S; Haimovich J; Hollander N
    Clin Exp Immunol; 2012 Dec; 170(3):291-9. PubMed ID: 23121670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade.
    Mao C; Beiss V; Ho GW; Fields J; Steinmetz NF; Fiering S
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.
    Brody JD; Goldstein MJ; Czerwinski DK; Levy R
    Blood; 2009 Jan; 113(1):85-94. PubMed ID: 18812472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming.
    Aleynick M; Svensson-Arvelund J; Pantsulaia G; Kim K; Rose SA; Upadhyay R; Yellin M; Marsh H; Oreper D; Jhunjhunwala S; Moussion CC; Merad M; Brown BD; Brody JD
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37487664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.